Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27069740 | 0.92 | MEN1 (0.31) | MEN1POLBKMT2A | |
| SCHEMBL98756 | 0.92 | MEN1 (0.33) | MEN1POLBKMT2A | |
| SCHEMBL27069754 | 0.90 | MEN1 (0.30) | MEN1POLBKMT2A | |
| SCHEMBL15471304 | 0.88 | CYP1A2 (0.36) | — | |
| SCHEMBL27069805 | 0.88 | — | — | |
| SCHEMBL13884285 | 0.86 | — | — | |
| SCHEMBL15471309 | 0.84 | MEN1 (0.35) | MEN1POLBKMT2A | |
| SCHEMBL27069825 | 0.82 | — | — | |
| SCHEMBL15471302 | 0.79 | — | — | |
| SCHEMBL23661926 | 0.79 | SIGMAR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-07-22 | — | — | US | disclosed |
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-03-30 | — | — | US | disclosed |
| US-20200261544-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| US-10682395-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2020-06-16 | — | — | US | disclosed |
| US-20190192634-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2019-06-27 | — | — | US | disclosed |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| US-9919033-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| US-9919033-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2017-03-02 | — | — | US | disclosed |
| US-9511122-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-12-06 | — | — | US | disclosed |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-07-21 | — | — | US | disclosed |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-07-21 | — | — | US | disclosed |
| US-9272048-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-03-01 | — | — | US | disclosed |
| US-9272048-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-03-01 | — | — | US | disclosed |
| US-20120322721-A1 | DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2012-12-20 | — | — | US | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA AS (DK) | 2011-05-12 | — | — | US | disclosed |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA AS (DK) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322721-A1 | DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER | GHRHR, GHSR, GCG | MEN1 402/4885POLB 3675/4885KMT2A 1703/4885 |
| US-20200261544-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | MEN1 402/4885POLB 3675/4885KMT2A 1703/4885 |
| US-10960053-B2 | PEGylated recombinant human growth hormone compounds | GHRHR, GHITM, GHSR | MEN1 672/4885POLB 2582/4885KMT2A 2937/4885 |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | MEN1 402/4885POLB 3675/4885KMT2A 1703/4885 |
| US-20190192634-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | MEN1 672/4885POLB 2582/4885KMT2A 2937/4885 |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | GHRHR, GHITM, GHSR | MEN1 672/4885POLB 2582/4885KMT2A 2937/4885 |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | MEN1 672/4885POLB 2582/4885KMT2A 2937/4885 |
| US-20210220442-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | MEN1 672/4885POLB 2582/4885KMT2A 2937/4885 |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | MEN1 402/4885POLB 3675/4885KMT2A 1703/4885 |
| US-10682395-B2 | Dry growth hormone composition transiently linked to a polymer carrier | GHRHR, GHSR, GCG | MEN1 402/4885POLB 3675/4885KMT2A 1703/4885 |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | MEN1 4083/4885POLB 233/4885KMT2A 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.